Repatha Significantly Improved Cholesterol Levels in High-Risk Patients with Type 2 Diabetes
June 26th 2018New data demonstrate that evolocumab (Repatha) significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with type 2 diabetes plus hypercholesterolemia or mixed dyslipidemia.
Read More
Relapsed/Refractory Multiple Myeloma Treatment Improves Progression-Free Survival in Study
June 26th 2018Elotuzumab with pomalidomide and low-dose dexamethasone met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.
Read More
FDA Approves Plazomicin for Treatment of Complicated Urinary Tract Infection
June 26th 2018Officials with the FDA have approved plazomicin (Zemdri, Achaogen) for the treatment of adults with complicated urinary tract infections (cUTIs), caused by certain Enterobacteriaceae, in patients with limited or no alternative treatment.
Read More
FDA Approves Groundbreaking Drug for Treating Rare, Severe Forms of Epilepsy
June 25th 2018Officials with the FDA have approved cannabidiol oral solution (Epidiolex) for the treatment of seizures associated with 2 rare and severe forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome, in patients aged 2 years and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and is the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
Read More
New Data Show Oral Semaglutide Significantly Reduced A1C in Adults with Type 2 Diabetes
June 25th 2018Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes.
Read More